Eli Lilly And Co patents expiration
1. Axiron patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6923983 | ELI LILLY AND CO | Transdermal delivery of hormones |
Feb, 2017
(7 years ago) | |
| US8071075 | ELI LILLY AND CO | Dermal penetration enhancers and drug delivery systems involving the same |
Feb, 2017
(7 years ago) | |
| US6818226 | ELI LILLY AND CO | Dermal penetration enhancers and drug delivery systems involving same |
Feb, 2017
(7 years ago) | |
| US6299900 | ELI LILLY AND CO | Dermal penetration enhancers and drug delivery systems involving same |
Feb, 2017
(7 years ago) | |
| US8784878 | ELI LILLY AND CO | Transdermal delivery rate control using amorphous pharmaceutical compositions |
Jul, 2023
(9 months ago) | |
| US8993520 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(2 years from now) | |
| US9180194 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Jun, 2026
(2 years from now) | |
| US9289586 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(2 years from now) | |
| US8419307 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(2 years from now) | |
| US8807861 | ELI LILLY AND CO | Spreading implement |
Feb, 2027
(2 years from now) | |
| US8435944 | ELI LILLY AND CO | Method and composition for transdermal drug delivery |
Sep, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 23, 2013 |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 23 November, 2010
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone; A method of transdermally delivering testosterone; A method of increasing t...
Dosage: SOLUTION, METERED;TRANSDERMAL
AXIRON family patents
2. Humalog Kwikpen patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6551992 | ELI LILLY AND CO | Stable insulin formulations |
Jun, 2018
(5 years ago) | |
| US6034054 | ELI LILLY AND CO | Stable insulin formulations |
Jun, 2018
(5 years ago) | |
| US7291132 | ELI LILLY AND CO | Medication dispensing apparatus with triple screw threads for mechanical advantage |
Aug, 2024
(3 months from now) | |
Drugs and Companies using INSULIN LISPRO RECOMBINANT ingredient
Market Authorisation Date: 26 May, 2015
Treatment: Treatment of irritable bowel syndrome with diarrhea (ibs-d) in adults and symptoms thereof.
Dosage: SOLUTION;SUBCUTANEOUS
HUMALOG KWIKPEN family patents
3. Mounjaro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(6 years from now) | |
| US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(7 years from now) | |
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 July, 2023
Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus
Dosage: SOLUTION;SUBCUTANEOUS
MOUNJARO family patents
4. Olumiant patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(4 years from now) | |
| US11806555 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(7 years from now) | |
| US9737469 | ELI LILLY AND CO | Methods for treating hair loss disorders |
Nov, 2031
(7 years from now) | |
| US9089574 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
Nov, 2032
(8 years from now) | |
| US11045474 | ELI LILLY AND CO | Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections |
Nov, 2032
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-890) | Jun 13, 2025 |
| New Indication(I-891) | May 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | May 31, 2023 |
Drugs and Companies using BARICITINIB ingredient
NCE-1 date: 31 May, 2022
Market Authorisation Date: 08 October, 2019
Treatment: Treatment of rheumatoid arthritis; Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-i...
Dosage: TABLET;ORAL
OLUMIANT family patents
5. Prozac patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6960577 | ELI LILLY AND CO | Combination therapy for treatment of refractory depression |
Nov, 2017
(6 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-589) | Mar 19, 2012 |
| New Patient Population(NPP) | Jul 26, 2016 |
Drugs and Companies using FLUOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 23 December, 1992
Treatment: Prozac and olanzapine in combination for the acute treatment of treatment resistant depression in adults
Dosage: CAPSULE;ORAL
PROZAC family patents
6. Reyvow patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7423050 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Feb, 2028
(3 years from now) | |
| US11053214 | ELI LILLY AND CO | Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists |
Dec, 2037
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8748459 | ELI LILLY AND CO | Pyridinoylpiperidines as 5-HT1F agonists |
Mar, 2023
(1 year, 1 month ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 31, 2025 |
Drugs and Companies using LASMIDITAN SUCCINATE ingredient
NCE-1 date: 01 February, 2024
Market Authorisation Date: 31 January, 2020
Treatment: Acute treatment of migraine
Dosage: TABLET;ORAL
REYVOW family patents
7. Verzenio patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7855211 | ELI LILLY AND CO | Protein kinase inhibitors |
Dec, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Oct 12, 2024 |
| New Indication(I-877) | Oct 12, 2024 |
| New Chemical Entity Exclusivity(NCE) | Sep 28, 2022 |
| New Indication(I-768) | Feb 26, 2021 |
Drugs and Companies using ABEMACICLIB ingredient
NCE-1 date: 28 September, 2021
Market Authorisation Date: 28 September, 2017
Treatment: In combination with fulvestrant for the treatment of adult patients with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progres...
Dosage: TABLET;ORAL
VERZENIO family patents
8. Zepbound patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9474780 | ELI LILLY AND CO | GIP and GLP-1 co-agonist compounds |
Jan, 2036
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8734394 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Feb, 2031
(6 years from now) | |
| US9402957 | ELI LILLY AND CO | Automatic injection device with delay mechanism including dual functioning biasing member |
Jun, 2031
(7 years from now) | |
| US11357820 | ELI LILLY AND CO | GIP/GLP1 agonist compositions |
Jun, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Nov 08, 2026 |
| New Chemical Entity Exclusivity(NCE) | May 13, 2027 |
Drugs and Companies using TIRZEPATIDE ingredient
NCE-1 date: 13 May, 2026
Market Authorisation Date: 28 March, 2024
Treatment: NA
Dosage: SOLUTION;SUBCUTANEOUS
ZEPBOUND family patents